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INTRODUCTION 
 
Improvements in diagnostic accuracy are needed for treatment of ovarian tumor.  
The treatment of ovarian cystic tumors remains some problems. Should they be 
removed because of the carcinoma risk or should they be left in order to preserve 
fertility? The establishment of a detection system for gene mutations in cystic fluid 
might help to determine malignancy without requiring the resection of the tumor 
tissues. 
     We investigated p53 gene expression and its mutation in the cystic fluid from 
patients with benign and malignant tumors to determine whether it reflects the 
molecular status of the cyst wall tissue. 
 
 
SUBJECTS AND METHODS 
 
  Forty-eight patients with ovarian cystic tumors participated in this study. All patients 
had a laparotomy or laparoscopic surgery at the Department of Obstetrics and 
Gynecology, Kochi Medical School, from April 2004 to December 2011. The 48 
patients included 31 with benign cysts, 10 with malignant tumors and 7 with borderline 
malignancy. This study was approved by the Institutional Review Board of Kochi 
Medical School Hospital. 
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     Ovarian tumor tissue, the corresponding ovarian cystic fluid, and peripheral 
blood (PB) samples were obtained at surgery. The PB and ovarian cystic fluid samples 
were frozen and stored at -80 until DNA extraction. 
After DNA extraction from the cystic fluid, polymerase chain reaction (PCR) 
and sequence analysis for exons 4-9 of the p53 was performed. In two cases of 
mucinous cystic tumor of borderline malignancy and endometioid adenocarcinoma, the 
p53 gene sequencies were determined. Furthermore, immunohistochemical staning for 
abnormal p53 gene product was performed. 
 
 
RESULTS 
 
     DNA was successfully extracted from all cystic fluid specimens of at least 1 ml 
regardless of the histlogical types of the tumor. After 35 cycles of PCR on extracted 
DNA using each set of primers, exons 4-9 of p53 gene were identified by 
electrophoresis for all types of ovarian cyst. 
     In one case with a mucinous cystic tumor of borderline malignancy, a point 
mutation in exon 6 at codon 223 (CCT→CTT) was detected by the direct sequencing of 
the amplified Exon. Notably, the mutation was not present in the PB sample from the 
patient. 
     In another case with a endometrial adenocarcinoma, a point mutation in exon 7 
at codon 245 (GGC→AGC) was detected by the direct sequencing of the amplified 
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Exon. Notably, the mutation was not present in the PB sample and tissue specimens 
from the patient. 
In our study, there is no p53 mutation in both cystic fluid and tissue from 
benign ovarian cyst. p53 mutation were identified in 12.5% (1/8) both of cystic fluid 
and tissue from borderline malignancy. They were identified in 10% (1/10) of cystic 
fluid with malignancy, but there is no mutation of p53 in tissue from malignancy. 
 
 
CONCLUSION 
 
     Concerning with cystic ovarian tumors, cystic fluid may provide informative 
material for molecular studies since it reflects the p53 status of tumor tissue on the cyst 
wall. We conclude that further gene studies may contribute to establish a new detection 
system for the presence of malignancies of cystic ovarian tumors. This system might 
help to identify ovarian malignant without resection of the tumor tissues. 
